Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Preprint
Abstract
Background: The role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) drugs in the management of diabetes and cardiovascular disease is well-established, but emerging evidence suggests potential effects on cancer outcomes, including gastrointestinal (GI) cancers. We conducted an extensive, sex-oriented, real-world data analysis to investigate whether SGLT2i can enhance GI cancer outcomes when used alongside standard therapies such as chemotherapy and radiotherapy. Methods: The study applied a retrospective cohort design with data from the TriNetX research database ( https://trinetx.com ), examining GI cancer patients treated with chemotherapy and/or radiotherapy between 2013 and 2023. The intervention cohort consisted of Gl cancer patients who received SGLT2i, while the control cohort did not. A 5-year follow-up period was used, and baseline characteristics were balanced using a 1:1 propensity score matching technique. Cox proportional-hazards and logistic regression models assessed mortality and morbidity risks between the cohorts. Results: The study included 6,389 male and 3,457 female patients with GI cancer (ICD-10: C15-C25). The use of SGLT2i was significantly associated with improved survival for both male (HR 0.568; 95% CI 0.534-0.605) and female (HR 0.561; 95% CI 0.513-0.614) patients undergoing chemotherapy and/or radiotherapy. SGLT2i use also correlated significantly with lower hospitalisation rates both in male (OR 0.684; 95% CI 0.637-0.734) and female (OR, 0.590; 95% CI 0.536-0.650) patients. The analysis of GI cancer subtypes also demonstrated similar benefits, without significant adverse effects. Conclusions: Repurposing SGLT2 inhibitors for cancer treatment could potentially improve outcomes for GI cancer patients without causing significant side effects. Further clinical trials are needed to confirm these findings and establish the optimal condition for its application in GI cancer treatment.Keywords
All Related Versions
- Published version: BMC Cancer, 25 (1), 1.
This publication has 73 references indexed in Scilit:
- Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort studyGastric Cancer, 2024
- Type 2 Diabetes and Colorectal Cancer RiskJAMA Network Open, 2023
- A preponderance of gastrointestinal cancer patients transition into cachexia syndromeJournal of Cachexia, Sarcopenia and Muscle, 2022
- Prevalence of diabetes mellitus among 80,193 gastrointestinal cancer patients in five European and three Asian countriesJournal of Cancer Research and Clinical Oncology, 2021
- Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer AuditGastric Cancer, 2021
- Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A ReviewReviews in Endocrine and Metabolic Disorders, 2021
- SGLT2 and cancerPflügers Archiv - European Journal of Physiology, 2020
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptakeInternational Journal of Cancer, 2017
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trialsDiabetologia, 2017
- Evidence for the contribution of insulin resistance to the development of cachexia in tumor‐bearing miceInternational Journal of Cancer, 2009